Tag : non-small cell lung cancer

Healthcare Quality, Patient Safety & Policy

Dizal’s ZEGFROVY® Gets FDA Accelerated Approval for NSCLC Treatment

PR Newswire
Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced today that the U.S. Food and...
Clinical Research, Pharma & Healthcare Financing

Dizal Completes Enrollment for Phase III Sunvozertinib NSCLC Study

PR Newswire
Dizal announced the completion of patient enrollment for its WU-KONG28 clinical trial: a multinational, randomized phase III study evaluating the efficacy and safety of sunvozertinib versus...
Clinical Research, Pharma & Healthcare Financing

Dizal to Present Cancer Drug Advances at ASCO 2025

PR Newswire
Dizal, a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced today that it will present latest clinical...